It was a busy week for the biotech sector. While the fourth-quarter earnings season continues, other pipeline and regulatory ...

The FDA has accepted a priority review of a new biannual HIV prevention injection, with a decision expected by June 19, 2025.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submissions for lenacapavir—the company’s twice-yearly ...

Trump has drummed up an inexplicable animus to our good neighbors and best trading partners. With tariffs, he is planning to ...

Lenacapavir is a twice-yearly injectable medication designed to be used as pre-exposure prophylaxis (PrEP). The FDA is giving ...

The Food and Drug Administration (FDA) has accepted under Priority Review the New Drug Application (NDA) for lenacapavir, a long-acting HIV-1 capsid inhibitor, for the prevention of HIV as ...

Lenacapavir is already approved under the name Sunlenca as an HIV treatment for patients resistant to other medication ...

Researchers have identified key immunological markers associated with mortality in hospitalised people living with HIV/AIDS.

Senior Economist Xhanti Payi predicts that discussions about the long-term sustainability of HIV/AIDS treatment will take ...

Health scholar explains why that leaves healthcare in Africa on brink of crisis INTERVIEW | U.S. President Donald Trump has announced that the U.S. will leave the World Health Organisation. And a ...

As US President Trump promised, its “America First.” One of the first Executive Orders he signed was to pause/cut foreign aid ...

In 2022, Holden’s play was nominated for Best New Play at the Olivier Awards, given for excellence in West End productions.